Canada’s Drug Agency (CDA-AMC) recommends that Alyftrek be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 6 years or older who have at least one F508del mutation or another responsive mutation in the CFTR gene (identified in Table 1 of this document), if certain conditions are met.
